|
1) アミロイドーシスに関する調査研究班, 編. アミロイドーシス診療ガイドライン2010. 2010
|
|
|
|
|
2) Westermark P, Natvig JB, Johansson B. Char-acterization of an amyloid fibril protein from senile cardiac amyloid. J Exp Med. 1977; 146: 631-6
|
|
|
|
|
3) Westermark P, Johansson B, Natvig JB. Senile cardiac amyloidosis: evidence of two different amyloid substances in the ageing heart. Scand J Immunol. 1979; 10: 303-8
|
|
|
|
|
|
4) Kyle RA, Spittell PC, Gertz MA, et al. The pre-mortem recognition of systemic senile amyloido-sis with cardiac involvement. Am J Med. 1996; 101: 395-400
|
|
|
|
|
|
5) Sletten K, Westermark P, Natvig JB. Senile cardiac amyloid is related to prealbumin. Scand J Immunol. 1980; 12: 503-6
|
|
|
|
|
|
6) Pitkanen P, Westermark P, Cornwell GG, 3rd. Senile systemic amyloidosis. Am J Pathol. 1984; 117: 391-9
|
|
|
|
|
|
7) Westermark P, Sletten K, Johansson B, et al. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A. 1990; 87: 2843-5
|
|
|
|
|
|
8) Cornwell GG, III., Murdoch WL, Kyle RA, et al. Frequency and distribution of senile cardiovas-cular amyloid. A clinicopathologic correlation. Am J Med. 1983; 75: 618-23
|
|
|
|
|
|
9) Tanskanen M, Kiuru-Enari S, Tienari P, et al. Senile systemic amyloidosis, cerebral amyloid angiopathy, and dementia in a very old Finnish population. Amyloid. 2006; 13: 164-9
|
|
|
|
|
|
10) Ueda M, Horibata Y, Shono M, et al. Clinicopatho-logical features of senile systemic amyloidosis: an ante- and post-mortem study. Mod Pathol. 2011 Aug 5. [Epub ahead of print]
|
|
|
|
|
|
11) Yamano M, Azuma A, Yazaki M, et al. Early cardiac involvement in senile systemic amyloido-sis: a case report. Amyloid. 2008; 15: 54-9
|
|
|
|
|
|
12) Kodaira M, Sekijima Y, Tojo K, et al. Non-senile wild-type transthyretin systemic amyloidosis presenting as bilateral carpal tunnel syndrome. J Peripher Nerv Syst. 2008; 13: 148-50
|
|
|
|
|
|
13) Takei Y, Hattori T, Gono T, et al. Senile systemic amyloidosis presenting as bilateral carpal tunnel syndrome. Amyloid. 2002; 9: 252-5
|
|
|
|
|
|
14) Sekijima Y, Uchiyama S, Tojo K, et al. High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syn-drome: a common cause of carpal tunnel syn-drome in the elderly. Hum Pathol. 2011 Jul 4. [Epub ahead of print]
|
|
|
|
|
|
15) Sueyoshi T, Ueda M, Jono H, et al. Wild-type transthyretin-derived amyloidosis in various ligaments and tendons. Hum Pathol. 2011; 42: 1259-64
|
|
|
|
|
|
16) Sekijima Y, Wiseman RL, Matteson J, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell. 2005; 121: 73-85
|
|
|
|
|
|
17) Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid. 2006; 13: 236-49
|
|
|
|
|
|
18) Tojo K, Sekijima Y, Kelly JW, et al. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloido-genesis. Neurosci Res. 2006; 56: 441-9
|
|
|
|
|
19) Coelho T, Maia L, Martins da Silva A, et al. Tafamidis (Fx-1006A): a first-in-class disease-modifying therapy for transthyretin familial amyloid. Amyloid. 2010; 17 Suppl 1: 75-6
|
|
|
|
|
|
20) Alvarez R, Borland T, Chen Q, et al. ALN-TTR, an RNAi therapeutic for the treatment of trans-thyretinmediated amyloidosis. Amyloid. 2010; 17 Suppl 1: 51-2
|
|
|
|
|
|
21) Love KT, Mahon KP, Levins CG, et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A. 2010; 107: 1864-9
|
|
|
|
|
|
22) Benson MD, Kluve-Beckerman B, Zeldenrust SR, et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve. 2006; 33: 609-18
|
|
|
|
|
|
23) Kyle RA, Greipp PR, OʼFallon WM. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood. 1986; 68: 220-4
|
|
|
|
|
|
24) Matsuda M, Gono T, Morita H, et al. Peripheral nerve involvement in primary systemic AL amyloidosis: a clinical and electrophysiological study. Eur J Neurol. 2011; 18: 604-10
|
|
|
|
|
|
25) Dispenzieri A, Lacy MQ, Katzmann JA, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2006; 107: 3378-83
|
|
|
|
|
|
26) Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemo-therapy. Br J Haematol. 2003; 122: 78-84
|
|
|
|
|
|
27) Shi J, Guan J, Jiang B, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunc-tion and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A. 2010; 107: 4188-93
|
|
|
|
|
|
28) Kyle RA, Greipp PR. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc. 1983; 58: 665-83
|
|
|
|
|
|
29) Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 pa-tients. Blood. 1998; 91: 3662-70
|
|
|
|
|
|
30) Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004; 140: 85-93
|
|
|
|
|
|
31) Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007; 109: 492-6
|
|
|
|
|
|
32) Moreau P, Jaccard A, Benboubker L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diag-nosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood. 2010; 116: 4777-82
|
|
|
|
|
|
33) Kastritis E, Anagnostopoulos A, Roussou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexametha-sone. Haematologica. 2007; 92: 1351-8
|
|
|
|
|
|
34) Reece DE, Sanchorawala V, Hegenbart U, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood. 2009; 114: 1489-97
|
|
|
|
|